Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Clinical Effectiveness of Second-Line Sunitinib Following Immune-oncologic (IO) Therapy in Patients With Metastatic Renal Cell Carcinoma in the International Metastatic Renal Cell Carcinoma Database (IMDC)
Sponsor: Analysis Group, Inc.
This observational or N/A phase trial investigates Metastatic Renal Cell Carcinoma (mRCC) and is currently completed. Analysis Group, Inc. leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Feb 2025 — Present [monthly]
Completed
-
Sep 2024 — Feb 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jun 2023 — Jul 2024 [monthly]
Completed
-
Jan 2023 — Jun 2023 [monthly]
Completed
▶ Show 6 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
May 2021 — Dec 2022 [monthly]
Completed
-
Jan 2021 — May 2021 [monthly]
Completed
-
Jun 2020 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Feb 2020 — Jun 2020 [monthly]
Active Not Recruiting
-
Dec 2019 — Feb 2020 [monthly]
Active Not Recruiting
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Analysis Group, Inc.
- International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .